PubMed Health⌕ Search

Biomedical subjects

F Papola

Publications and source records attributed to F Papola.

36 records · Page 2Linked to original sources
PubMed1989

HLA antigens and infantile psoriasis.

The frequency distribution of HLA-A, -B, -C and -DR antigens in a group of 52 unrelated psoriatic patients, aged from 0 to 12 years, selected according the following four clinical subsets: guttate, inverted, follicular and minimal, was evaluated. A statistical analysis on 85 infantile psoriatic patients, randomly selected, and divided into two groups according to the age of onset of the disease, was also performed. The results show an increase of HLA-B27 antigen in the minimal psoriasis, A2 in the guttate form and of B41 allele in the inverted psoriasis. A significantly prevalence of CW6 antigen either in follicular subset or in total psoriatic patients or in both groups of age was observed, showing a strict association with the disease. An increase of HLA-B17, CW6 and DR6 in the total psoriatic patients was also noticed. The authors underline the prognostic value of this analysis.

Age Factors↗
PubMed1986

Radioimmunoassay typing gives a more precise definition of the HLA association of type 1 (insulin-dependent) diabetes.

The problem of the HLA association of Type 1 (insulin-dependent) diabetes was re-examined by testing Class II antigenic specificities detectable by radioimmunoassay. Established (DRw53, DQw1, DQw2, DQw3) as well as newly described (DC5, DCalpha3) specificities were typed. The data obtained suggest that the association with DR3 and DR4 is secondary to that with DQ specificities in linkage disequilibrium with DR3 and DR4.

Diabetes Mellitus, Type 1↗
PubMed1986

T-lymphocyte subsets modifications in multiple sclerosis: correlation with clinical disease activity.

Serial analyses of peripheral blood T-lymphocyte subsets were performed in 280 samples collected over a 27 months period from 14 multiple sclerosis patients. A significant decrease of T8+ cells was found in 47.1% (47/87) of blood samples collected within four weeks of onset of a relapse opposed to 2.1% (1/47) of samples collected during the four weeks before a relapse and to 3.4% (5/146) of those collected over four weeks after a relapse. Changes of T-cells subsets appear to correlate with disease activity, but normal findings observed before relapses suggest that the decrease of T8+ cells cannot be used as valid predictor of relapse.

Antigens, Differentiation, T-Lymphocyte↗
PubMed1983

[Separation of monocytes and their use in a cytotoxicity test].

Observations of acute rejections in uremic patients transplanted with Kidney grafts from Human Leucocyte Antigens (HLA) identical or compatible donors have suggested the importance of the role play by antigens not codified by the Major Histocompatibility Complex (MHC). Some works detected anti-monocytes antibodies that could not be absorbed with platelets (HLA-ABC) or with B lymphocytes (HLA-DR) or granulocytes but only with endothelial cells. Since endothelial cells and monocytes share not HLA surface determinants. Methods to isolate monocytes and endothelial cells have been attempted. We isolated monocytes by Percoll gradients. We checked the purity of our cell population by using monoclonal monocytes. From 30 ml of whole blood we obtained a mean of 50 X 10(6) (min. 12, 6 X 10(6) max 14 X 10(-6] mononuclear cells. After centrifugation of Percoll gradients we recovered a mean 7, 8 X 10(6) cells (Low 1, 3 X 10(6); max. 15 X 10(6] in the monocytes interface. By testing with monoclonal antibodies we found that a mean of 68, 95% (min. 58%; max. 82%) of these cells were living monocytes. We used the cell suspension to detect anti-monocyte antibodies in sera from 171 politransfused uremic patients with long incubation NIH cytotoxicity test.

Antigens, Surface↗
PubMed1983

[Specific antibodies against lymphocytes and monocytes in multiple-transfused uremic patients].

Kidney patients waiting for transplant usually undergo deliberate transfusion without clinical need in order to improve the outcome of the transplantation. Besides the beneficial transfusion effect on graft survival antibodies against the Major Histocompatibility Complex (MHC) can be detected after blood transfusions. Preliminary studies have shown antibodies against surface determinants of endothelial cells and monocytes too. Following that it is necessary to investigate how these different antibodies can affect the kidney allograft survival in politransfused uremic patients. We tested 171 sera from uremic patients to detect antibodies directed against T and B lymphocytes and monocytes by using long incubation standard NIH cytotoxicity technique. Antibodies against B cells have been tested at 20 degrees C and 4 degrees C. 54 patients (31,6%) showed anti-HLS antibodies: sera from 23 patients (13,5%) were positive against I and B cells (T+B+) and monocytes (M+) and that's probably due to anti-HLA-A,B,C and DR antibodies. 17 patients (9,9%) were T+B+ for the presence of anti HLA- A,B,C antibodies. 10 patients (5,8%) were T+. It is not yet clear why 18 patients (10,5%) showed anti B Lymphocytes antibodies tested at 20 degrees C. Probably the presence of anti HLA-DR antibodies caused the positivity of 4 B+M+ patients (2,33%). Sera from 5 patients (2,92%) showed anti B Lymphocytes antibodies tested at 4 degrees C. 21 patients (12,3%) were M+ only.

Antibodies↗
PubMed1981

[Preliminary considerations on the occurrence of antigens of the HLA system in a group of chronic glomerulonephritis patients].

80 patients affected by Cronic Glomerulonephritis have been typed for HLA-A-B-C locuses, using a standard NIH Microfinphotoxicity Technique. 66 healthy blood donors have been types as controls. A significantly increased frequency of HLA-Bw35 has been reported in the patients group. Further analysis is needed for definite conclusions about linkage between this disease and HLA antigens.

Chronic Disease↗
PubMedDate not supplied

Waiting list for kidney transplants.

Medical and technological progress have made kidney transplants an effective, alternative therapy to dialysis for patients suffering from chronic kidney failure. Transplantation improves the quality of life of these patients significantly; however, waiting lists are long and this is because of the attitude of the general public to organ donation, not a lack of medical expertise. In fact, the only limiting factor in kidney transplant is the opposition to donation expressed by the deceased or family members. Herein we outline the distribution of patients on the kidney transplant waiting list in the Regional Transplant Centre for Abruzzo and Molise in L'Aquila, Italy, and highlight the reasons why patients are withdrawn from the list, the main reason being a deterioration in patient condition after long periods of dialysis.

Humans↗
PubMedDate not supplied

The role of DRB1 amino acid residue differences on donor-specific antibody production and acute rejection after cadaveric renal transplant.

The correlation between DRB1 amino acid residue matching, post-transplant humoral response and acute rejection (ARj) episodes was analysed in 51 renal transplant donor-recipient pairs in order to determine new criteria for organ assignment based on the alloreactivity of the residue within the peptide binding groove. HLA class I and II compatibility was defined using serological and genomic techniques; a sequence-based typing (SBT) was used for a higher resolution of DRB1 alleles. Humoral response was monitored in the first post-transplant year using triple staining flow cytometric analysis of donor-specific antibodies (Abs). Our data showed that DRB1 residue compatibility was always correlated to the absence of ARj while the presence of one or more aminoacid differences was associated with a similar frequency of ARj. Analysis of the mismatched DRB1 amino acid residue localised in the beta-pleated sheet and the alpha-helix of the DRB 1 molecule revealed that the frequency of beta-pleated sheet residue mismatches (MMs) was higher in the ARj-positive than in the ARj-negative group. A significant increase in the alpha-helix residue MMs was observed in patients with anti-class II Ab production (p = 0.034). Furthermore, analysing in detail DRB 1 MMs at the level of single amino acid residue, we found that the frequency of the mismatches localized in codon 9 and codon 28 in the beta-pleated sheet, as well as in codon 57 in the alpha-helix, was higher in patients who experienced ARj; on the other hand, MMs in codon 58 of the alpha-helix were more frequently associated with anti-class II Ab production. The identification of the residues more involved in alloreactivity onset will make it possible to define the existence of "permissive" or immunogenic" allele combinations which could simplify and increase the chances of a successful transplant.

Amino Acids↗
PubMedDate not supplied

[p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].

MATERIAL AND METHODS: The authors carried out a p53 genetic research on native DNA in 15 oral-maxillofacial squamous cell carcinomas, lymph nodes metastasis, treated with neoadjuvant chemotherapy, checking the p53 "status" and the clinical response to the chemotherapeutic treatment (three 5-FU/CDDP cycles). RESULTS: The authors found p53 mutations in 3/15 cases. In these cases, at post-chemo restaging, it resulted 2 progressions and 1 stability of disease. In the 12 cases with wildtype p53: 4 objective improvements and partial responses (PR), respectively, of 55% (1), 60% (1), 65% (1), 70% (1), 75% (2) and 90% (2). The 15 patients were treated then by surgery and adjuvant chemotherapy (three C-F cycles). These results seem to confirm the outcome of the researches "in vitro" and they provide first correlations between p53 mutations and chemoresistance in oral squamous cell carcinomas. The survival evaluation also, in the examined cases, shows, but with medium-term follow-up, the tendency to a poor prognosis when p53 is altered. CONCLUSIONS: This research outlines the possibility, also for oral and maxillofacial tumors, to utilize, p53 as a prognostic and chemoresponse marker, useful, with the otherwise well-known prognostic factors, for the evaluation of advanced cancers, in the interests of a more suitable therapeutic protocol.

Aged↗